Any apneic episodes · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower any apneic episodes compared with placebo or control (moderate certainty).
1 finding from 1 review
Failed apnea reduction · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower failed apnea reduction compared with placebo or control (moderate certainty).
1 finding from 1 review
Positive‐pressure ventilation after institution of treatment · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine may leads to lower positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (high certainty).
1 finding from 1 review
Overall autism features Not assessed · children and adolescents with a diagnosis of autism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repetitive and restricted behaviour (Sensory Motor subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Side effects or other adverse events · children and adolescents with a diagnosis of autism
1 finding from 1 review
Irritability · children and adolescents with a diagnosis of autism
1 finding from 1 review
Hyperactivity (Child Behaviour Checklist Attention problems Subscale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
General health and function (Severity of Illness subscale of Clinical Global Impression Scale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Social communication (Lethargy/Social withdrawal subscale of the ABC‐C; 0 to 64; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Stereotypical behaviours · children and adolescents with a diagnosis of autism
1 finding from 1 review
Side effects or other adverse events · children and adolescents with a diagnosis of autism
Galantamine plus risperidone may leads to higher adverse events (Side Effects Checklist) compared with placebo plus risperidone (low certainty).
1 finding from 1 review
Irritability · children and adolescents with a diagnosis of autism
1 finding from 1 review
Hyperactivity · children and adolescents with a diagnosis of autism
1 finding from 1 review
General health and function Not assessed · children and adolescents with a diagnosis of autism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall autism features (total score of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Social communication (Social Relationships subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
1 finding from 1 review
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review